Status:
NOT_YET_RECRUITING
Efficacy of Gut-Brain Neuromodulators for Functional Dyspepsia
Lead Sponsor:
RenJi Hospital
Conditions:
Functioanl Dyspepsia
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The use of Neuromodulators is now recognized by international consensus as effective in improving Disorders of Gut-Brain Interaction (DGBIs). However, the digestive mind-body concept of therapeutic dr...
Eligibility Criteria
Inclusion
- adult patients with primary FD who meet the diagnostic criteria for Roman IV;
- able to complete the questionnaire, trial evaluation and sign the written informed consent.
Exclusion
- organic gastrointestinal diseases by gastroenteroscopy within 6 months;
- severe insufficiency of heart, liver, kidney, lung and other important organs and with congenital diseases;
- allergic to the drugs used in this study
- being pregnant, lactating or planning to become pregnant;
- are taking or have taken monoamine oxidase inhibitors within the past 5 weeks;
- have a known risk of narrow angle glaucoma.
Key Trial Info
Start Date :
April 10 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 10 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06931223
Start Date
April 10 2025
End Date
September 10 2025
Last Update
April 17 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.